临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 129497-78-5

Verteporfin (CL 318952)

中文名称:维替泊芬
CAS号:129497-78-5
分子式: C41H42N4O8 分子量: 718.79
产品形式: free base
研发状态: Recruiting
研发用途: Glioblastoma; Recurrent Glioblastoma
研究机构: Emory University; National Cancer Institute (NCI)
研发日期: January 15 2021
研发阶段: Phase 1 : Phase 2
Verteporfin (CL 318952, Visudyne) is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.

CAS: 129453-61-8

Fulvestrant (ICI-182780)

中文名称:氟维司琼
CAS号:129453-61-8
分子式: C32H47F5O3S 分子量: 606.77
产品形式: free base
研发状态: Recruiting
研发用途: Advanced Cancer; Breast Cancer
研究机构: OnKure Inc.
研发日期: March 1 2024
研发阶段: Phase 1
Fulvestrant (ICI-182780, ZD 9238, ZM 182780) is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay. Fulvestrant also induces autophagy and apoptosis and has antitumor activity.

CAS: 1291074-87-7

ENMD-2076 L-(+)-Tartaric acid

中文名称:ENMD-2076 酒石酸盐
CAS号:1291074-87-7
分子式: C25H31N7O6 分子量: 525.56
产品形式: free base
研发状态: Completed
研发用途: Relapsed or Refractory Hematological Malignancies
研究机构: CASI Pharmaceuticals Inc.
研发日期: Apr-09
研发阶段: Phase 1
ENMD-2076 L-(+)-Tartaric acid is the tartaric acid of ENMD-2076, selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold more selective for Aurora A than Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. Phase 2.

CAS: 129101-54-8

Rivastigmine Tartrate

中文名称:酒石酸卡巴拉汀
CAS号:129101-54-8
分子式: C14H22N2O2.C4H6O6 分子量: 400.42
产品形式: Tartrate
研发状态: Recruiting
研发用途: Depressive Disorder
研究机构: UMC Utrecht; ZonMw: The Netherlands Organisation for Health Research and Development; St. Antonius Hospital; Tergooi Hospital
研发日期: September 29 2021
研发阶段: Phase 4
Rivastigmine Tartrate (ENA 713) is a cholinesterase inhibitor with IC50 of 5.5 μM, and used as a parasympathomimetic or cholinergic agent for the treatment of mild to moderate Alzheimer disease.

CAS: 1290543-63-3

Nirogacestat (PF-03084014)

CAS号:1290543-63-3
分子式: C27H41F2N5O 分子量: 489.64
产品形式: free base
研发状态: Withdrawn
研发用途: Breast Cancer
研究机构: Jules Bordet Institute
研发日期: Jun-15
研发阶段: Phase 2
Nirogacestat (PF-03084014, PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay. Nirogacestat (PF-03084014, PF-3084014) induces apoptosis. Phase 2.

CAS: 128794-94-5

Mycophenolate mofetil (RS-61443)

中文名称:吗替麦考酚酯
CAS号:128794-94-5
分子式: C23H31NO7 分子量: 433.49
产品形式: free base
研发状态: Not yet recruiting
研发用途: Hyperglycemia; Renal Transplant Complication Primary Non-Function; Diabetes
研究机构: Rigshospitalet Denmark; Aarhus University Hospital; Odense University Hospital
研发日期: April 1 2024
研发阶段: Phase 4
Mycophenolate Mofetil (RS 61443, Mycophenolic acid morpholinoethyl ester, CellCept, TM-MMF) is a non-competitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase I/II with IC50 of 39 nM and 27 nM, respectively. Mycophenolate Mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells.